# Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease

> **NCT00002652** · PHASE2 · COMPLETED · sponsor: **University of Arkansas**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **DRUG:** suramin

## Key facts

- **NCT ID:** NCT00002652
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1995-05
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** — (—)
- **Last updated:** 2013-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002652, "Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00002652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*